AUROPHARMA:NSE Aurobindo Pharma Limited

INR 1,344.55 13.75 1.033213
Icon

Aurobindo Pharma Limited (AUROPHARMA:NSE) Stock Analysis and Price Targets

COMMON STOCK | Drug Manufacturers - Specialty & Generic | NSE
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

INR 1,344.55

+13.75 (+1.03)%

INR 789.58B

1.40M

N/A

INR 1400.00 (+4.12%)

Icon

AUROPHARMA:NSE

Aurobindo Pharma Limited (INR)
COMMON STOCK | NSE
INR 1,344.55
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

INR 789.58B

INR 1400.00 (+4.12%)

INR 1,344.55

Aurobindo Pharma Limited (AUROPHARMA:NSE) Stock Forecast

INR 1,244.17
(-7.47%)

Based on the Aurobindo Pharma Limited stock forecast from 5 analysts, the average analyst target price for Aurobindo Pharma Limited is INR 1,244.17 over the next 12 months. Aurobindo Pharma Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aurobindo Pharma Limited is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, Aurobindo Pharma Limited’s stock price was INR 1,344.55. Aurobindo Pharma Limited’s stock price has changed by -2.20% over the past week, +8.34% over the past month and +72.48% over the last year.

No recent analyst target price found for Aurobindo Pharma Limited
No recent average analyst rating found for Aurobindo Pharma Limited

Company Overview Aurobindo Pharma Limited

Aurobindo Pharma Limited engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally. It offers formulation in form of orals, injectables and over-the-counter drugs; and active pharmace...Read More

https://www.aurobindo.com

Galaxy, Plot No. 1, Hyderabad, India, 500032

0

March

INR

India

Adjusted Closing Price for Aurobindo Pharma Limited (AUROPHARMA:NSE)

Loading...

Unadjusted Closing Price for Aurobindo Pharma Limited (AUROPHARMA:NSE)

Loading...

Share Trading Volume for Aurobindo Pharma Limited Shares

Loading...

Compare Performance of Aurobindo Pharma Limited Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AUROPHARMA:NSE

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Aurobindo Pharma Limited (Sector: Drug Manufacturers - Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE
Sun Pharmaceutical Industries .. +18.70 (+1.19%) INR3,781.34B 39.44 26.65

ETFs Containing AUROPHARMA

Symbol Name AUROPHARMA's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Aurobindo Pharma Limited (AUROPHARMA:NSE) Stock

Based on ratings from 5 analysts Aurobindo Pharma Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 5 buy, sell and 1 hold ratings.

AUROPHARMA:NSE stock's dividend yield is 0.34%. Our analysis grades AUROPHARMA:NSE stock's dividend yield at F. This means that AUROPHARMA:NSE stock's dividend yield is above 44% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange. Based on this AUROPHARMA:NSE may be a average dividend stock for its sector.

Based on targets from 5 analysts, the average taret price for AUROPHARMA:NSE is INR 1,244.17 over the next 12 months. The maximum analyst target price is INR 1475 while the minimum anlayst target price is INR 1150.

AUROPHARMA:NSE stock's Price/Earning ratio is 24.88. Our analysis grades AUROPHARMA:NSE stock's Price / Earning ratio at C. This means that AUROPHARMA:NSE stock's Price/Earning ratio is above 26% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange. Based on this AUROPHARMA:NSE may be undervalued for its sector.

The last closing price of AUROPHARMA:NSE's stock was INR 1,344.55.

The most recent market capitalization for AUROPHARMA:NSE is INR 789.58B.

Based on targets from 5 analysts, the average taret price for AUROPHARMA:NSE is projected at INR 1,244.17 over the next 12 months. This means that AUROPHARMA:NSE's stock price may go down by -7.47% over the next 12 months.

We can't find any ETFs which contains Aurobindo Pharma Limited's stock.

As per our most recent records Aurobindo Pharma Limited has 0 Employees.

Aurobindo Pharma Limited's registered address is Galaxy, Plot No. 1, Hyderabad, India, 500032. You can get more information about it from Aurobindo Pharma Limited's website at https://www.aurobindo.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...